Short Interest in Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Decreases By 15.1%

Antibe Therapeutics Inc. (OTCMKTS:ATBPFGet Rating) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totalling 29,700 shares, a drop of 15.1% from the August 15th total of 35,000 shares. Based on an average daily volume of 13,000 shares, the short-interest ratio is currently 2.3 days.

Analyst Ratings Changes

Separately, Brookline Capital Management reiterated a “buy” rating on shares of Antibe Therapeutics in a research note on Thursday, June 30th.

Antibe Therapeutics Trading Up 10.2 %

ATBPF opened at $0.52 on Friday. The firm has a 50-day moving average price of $0.48 and a 200-day moving average price of $0.53. Antibe Therapeutics has a twelve month low of $0.42 and a twelve month high of $1.07.

Antibe Therapeutics (OTCMKTS:ATBPFGet Rating) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. Equities research analysts anticipate that Antibe Therapeutics will post -0.31 EPS for the current fiscal year.

Antibe Therapeutics Company Profile

(Get Rating)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

Recommended Stories

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.